Dr Reddy’s reports muted Q1FY27 results, net profit drops 69%
Dr Reddy’s reports muted Q1FY27 results, net profit drops 69%
You are viewing a historical snapshot of India (NSE / BSE). These figures are a preview to show what TradeTidings covers. Live, continuously updated India sentiment and stock impact is a Pro feature.
Get live India data with ProOver the last 90 days, Pharmaceuticals shows 33 positive, 6 neutral and 18 negative news signals across its constituents. The auto-generated sector insight (top drivers with direction + rationale) appears here once the analysis worker has processed enough items.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
How news sentiment on the Pharmaceuticals sector has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
The most recent stories affecting Pharmaceuticals, across all of our coverage.
Dr Reddy’s reports muted Q1FY27 results, net profit drops 69%
Dr. Reddy's reported a 69% year-on-year PAT decline in Q1 FY27, driven by a steep fall in US generics revenue. The sharp miss signals mounting pressure on India's pharma exporters from global pricing erosion.
Cipla's profit declined in FY26, pressuring its share price by 2% and raising questions about the company's earnings trajectory amid sector-wide challenges.
The Nifty Pharma index declined nearly 2% as investors reacted to Trump's announcement of a 200% tariff on generic drugs. Cipla and Dr Reddy's were among the top losers, with both stocks pressured by concerns over US revenue impact.
Negotiations on a comprehensive India-EU trade pact are nearing completion, signaling potential tariff reductions and expanded market access for Indian exporters, particularly in pharma, IT, and specialty chemicals.
Cipla's US subsidiary received a single observation after a USFDA inspection of its New York manufacturing facility, a mild compliance flag investors will watch for a response before it escalates.
Alkem Laboratories finalizes acquisition of Occlutech Holding AG, strengthening its presence in specialty pharmaceutical segments.
Poly Medicure's management says new manufacturing facilities and products should help double the company's international business.
Sun Pharma has won approval to launch a generic version of semaglutide, sold as Ozempic and Wegovy, in South Africa.
Dr Reddy's Laboratories has halted manufacturing of the active ingredient used in its semaglutide products after an impurity was found, delaying a drug seen as a major growth driver.
Dr Reddy's Laboratories has set a target of producing 6 to 7 million semaglutide pens in FY27, underlining its push into the GLP-1 weight-loss and diabetes drug opportunity.
Zydus Lifesciences has agreed to a $150 million deal for Sterling Biotech's fermentation based manufacturing assets, adding API capacity to its pharmaceutical business.
A block deal worth Rs 1,839 crore in Biocon shares was executed, with ICICI Prudential Mutual Fund the top buyer alongside Citigroup and Goldman Sachs.
Syngene International has acknowledged strategic missteps in its CDMO business and outlined a turnaround plan, signalling management wants to fix underperformance in its core contract research and manufacturing unit.
Sun Pharma Advanced Research Company (SPARC) has appointed Anil Raghavan as MD and CEO from August 11, following a reported Rs 1,761 crore financial turnaround.
Torrent Pharmaceuticals is recalling certain batches of its Semalix injection pens after a notice from the manufacturer flagged an issue with the product.
Showing 1–16 of 50